Locally Recurrent Head and Neck Squamous Cell Carcinoma
Oncology·MeSH: Mouth Neoplasms
Prevalence
14.0 / 100K
Incidence
6.0 / 100K/yr
1 drug in development·1 company·2 clinical trials
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| Birinapant | IGM Biosciences, Inc. (IGMS) |
Frequently asked questions
How many drugs are in development for Locally Recurrent Head and Neck Squamous Cell Carcinoma?
BioSniper tracks 1 drug in development for Locally Recurrent Head and Neck Squamous Cell Carcinoma across 1 company.
How many clinical trials target Locally Recurrent Head and Neck Squamous Cell Carcinoma?
There are 2 clinical trials targeting Locally Recurrent Head and Neck Squamous Cell Carcinoma tracked by BioSniper.
What is the prevalence of Locally Recurrent Head and Neck Squamous Cell Carcinoma?
The estimated prevalence of Locally Recurrent Head and Neck Squamous Cell Carcinoma is approximately 14.0 per 100,000 population.
Deep-dive into Locally Recurrent Head and Neck Squamous Cell Carcinoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis